Rosabulin
Alternative Names: STA-5312Latest Information Update: 09 Oct 2008
At a glance
- Originator Synta Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haematological malignancies; Solid tumours
Most Recent Events
- 09 Oct 2008 Discontinued - Phase-I for Haematological malignancies in USA (IV)
- 09 Oct 2008 Discontinued - Phase-I for Solid tumours in USA (IV)
- 30 Dec 2005 This compound is still in active development